enGene Therapeutics Inc. (ENGN)
ENGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.63
-4.12% on the day
Market cap
$109.2M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ENGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001980845 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Z4 |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-09 |
| Latest annual report | 10-K/A | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-09-08 |
| Latest current report | 8-K | 2026-09-08 |
| Latest proxy | DEF 14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LENZ | LENZ Therapeutics Inc. | $3.40 | -5.82% | $106.8M |
| ARMP | Armata Pharmaceuticals Inc. | $3.10 | -14.60% | $115.3M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
| HUMA | Humacyte Inc. | $0.3589 | -7.88% | $99.7M |
| BDTX | Black Diamond Therapeutics Inc. | $1.68 | -5.08% | $96.5M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
| ABOS | Acumen Pharmaceuticals Inc. | $1.81 | -10.15% | $131.3M |
| VYGR | Voyager Therapeutics Inc. | $2.15 | -5.29% | $132.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier